Dhani: peers
Dhani beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.
Dhani: the market cap on file is more than 60 days old or a last known value (no market-data feed for its exchange yet), so its valuation multiples and yields are shown but not ranked.
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | Dhanibase DHANI.NS · 🇮🇳 IN Percentile in Healthcare Percentile in India | Dr. Reddy's Laboratories Limited DRREDDY.BO · 🇮🇳 IN Percentile in Healthcare Percentile in India | Sun Pharmaceutical Industries Limited SUNPHARMA.NS · 🇮🇳 IN Percentile in Healthcare Percentile in India | Divi's Laboratories Limited DIVISLAB.NS · 🇮🇳 IN Percentile in Healthcare Percentile in India | Cipla Limited CIPLA.BO · 🇮🇳 IN Percentile in Healthcare Percentile in India | Apollo Hospitals Enterprise Limited APOLLOHOSP.NS · 🇮🇳 IN Percentile in Healthcare Percentile in India | Torrent Pharmaceuticals Limited TORNTPHARM.NS · 🇮🇳 IN Percentile in Healthcare Percentile in India | Zydus Lifesciences Limited ZYDUSLIFE.NS · 🇮🇳 IN Percentile in Healthcare Percentile in India | Group median |
|---|---|---|---|---|---|---|---|---|---|
| Size | |||||||||
| Market cap (Better neither way: ranked highest first) | —— | $12.5 BNov 20, 2026 · Market data6th of 7 | $48.8 BNov 20, 2026 · Market data1st of 7 | $32.0 BNov 20, 2026 · Market data2nd of 7 | $12.3 BNov 20, 2026 · Market data7th of 7 | $14.3 BNov 20, 2026 · Market data4th of 7 | $19.2 BNov 20, 2026 · Market data3rd of 7 | $12.9 BNov 20, 2026 · Market data5th of 7 | $14.3 B7 ranked |
| Revenue (Better neither way: ranked highest first) | —— | $3.9 BFY2024 · SEConly one with it | —— | —— | —— | —— | —— | —— | $3.9 B— |
| Net income (Higher is better) | —— | $669 MFY2024 · SEConly one with it | —— | —— | —— | —— | —— | —— | $669 M— |
| Employees (Better neither way: ranked highest first) | —— | 24,795As on 2022 · Profile3rd of 7 | 36,000As on May 2021 · Profile2nd of 7 | 13,884As on March 2020 · Profile6th of 7 | 23,000As on 2018 · Profile5th of 7 | 83,147As on 2022 · Profile1st of 7 | 13,573As on 2022 · Profile7th of 7 | 23,026As on 2022 · Profile4th of 7 | 23,0267 ranked |
| Growth | |||||||||
| Revenue growth (Higher is better) | ———— | +14.2%FY2024 · SEConly one with it58th— | ———— | ———— | ———— | ———— | ———— | ———— | +14.2%— |
| Revenue growth, 3 years a year (Higher is better) | ———— | +10.2%FY2024 · SEConly one with it53rd— | ———— | ———— | ———— | ———— | ———— | ———— | +10.2%— |
| Earnings per share growth (Higher is better) | ———— | -0.6%FY2024 · SEConly one with it36th— | ———— | ———— | ———— | ———— | ———— | ———— | -0.6%— |
| Margins and returns | |||||||||
| Gross margin (Higher is better) | ———— | 58.5%FY2024 · SEConly one with it50th— | ———— | ———— | ———— | ———— | ———— | ———— | 58.5%— |
| Operating margin (Higher is better) | ———— | 22.1%FY2024 · SEConly one with it90th— | ———— | ———— | ———— | ———— | ———— | ———— | 22.1%— |
| Net margin (Higher is better) | ———— | 17.4%FY2024 · SEConly one with it88th— | ———— | ———— | ———— | ———— | ———— | ———— | 17.4%— |
| Free cash flow margin (Higher is better) | ———— | 5.8%FY2024 · SEConly one with it64th— | ———— | ———— | ———— | ———— | ———— | ———— | 5.8%— |
| Return on equity (Higher is better) | ———— | 18.4%FY2024 · SEConly one with it90th— | ———— | ———— | ———— | ———— | ———— | ———— | 18.4%— |
| Return on invested capital (Higher is better) | ———— | 17.7%FY2024 · SEConly one with it74th— | ———— | ———— | ———— | ———— | ———— | ———— | 17.7%— |
| Valuation | |||||||||
| P/E ratio (Better neither way: ranked highest first) | ———— | 27.1×price Nov 20, 2026 · Market data6th of 746th43rd | 39.4×price Nov 20, 2026 · Market data4th of 760th59th | 115.5×price Nov 20, 2026 · Market data1st of 790th93rd | 29.4×price Nov 20, 2026 · Market data5th of 749th46th | 68.1×price Nov 20, 2026 · Market data3rd of 780th81st | 82.4×price Nov 20, 2026 · Market data2nd of 785th86th | 23.7×price Nov 20, 2026 · Market data7th of 740th36th | 39.4×7 ranked |
| Price to sales (Better neither way: ranked highest first) | ———— | 3.5×price Nov 20, 2026 · Market data7th of 748th51st | 7.8×price Nov 20, 2026 · Market data3rd of 767th77th | 28.3×price Nov 20, 2026 · Market data1st of 787th97th | 4.1×price Nov 20, 2026 · Market data6th of 752nd55th | 5.3×price Nov 20, 2026 · Market data4th of 758th64th | 13.0×price Nov 20, 2026 · Market data2nd of 778th88th | 4.5×price Nov 20, 2026 · Market data5th of 755th57th | 5.3×7 ranked |
| Price to book (Better neither way: ranked highest first) | ———— | 3.0×price Nov 20, 2026 · Market data7th of 750th36th | 5.4×price Nov 20, 2026 · Market data4th of 769th57th | 17.7×price Nov 20, 2026 · Market data1st of 791st92nd | 3.3×price Nov 20, 2026 · Market data6th of 754th39th | 13.3×price Nov 20, 2026 · Market data2nd of 789th89th | 10.1×price Nov 20, 2026 · Market data3rd of 784th82nd | 4.0×price Nov 20, 2026 · Market data5th of 761st46th | 5.4×7 ranked |
| Free cash flow yield (Higher is better) | ———— | 1.8%price Nov 20, 2026 · Market dataonly one with it75th— | ———— | ———— | ———— | ———— | ———— | ———— | 1.8%— |
| Financial strength | |||||||||
| Debt to equity (Lower is better) | ———— | 0.0×FY2024 · SEConly one with it12th— | ———— | ———— | ———— | ———— | ———— | ———— | 0.0×— |
| Net debt to EBITDA (Lower is better) | ———— | -0.1×FY2024 · SEConly one with it25th— | ———— | ———— | ———— | ———— | ———— | ———— | -0.1×— |
| Interest cover (Higher is better) | ———— | 25.4×FY2024 · SEConly one with it96th— | ———— | ———— | ———— | ———— | ———— | ———— | 25.4×— |
| Piotroski F-score (Higher is better) | —— | 2 of 9FY2024 · SEConly one with it | —— | —— | —— | —— | —— | —— | 2.0 of 9— |
| Scorecard | |||||||||
| Scorecard (Higher is better) | —— | 24 of 30FY2024 · Scorecardonly one with it | —— | —— | —— | —— | —— | —— | 80% passed— |
| Valuation checks (Higher is better) | —— | 3 of 6FY2024 · Scorecardonly one with it | —— | —— | —— | —— | —— | —— | 50% passed— |
| Growth checks (Higher is better) | —— | 5 of 6FY2024 · Scorecardonly one with it | —— | —— | —— | —— | —— | —— | 83% passed— |
| Profitability checks (Higher is better) | —— | 6 of 6FY2024 · Scorecardonly one with it | —— | —— | —— | —— | —— | —— | 100% passed— |
| Financial health checks (Higher is better) | —— | 6 of 6FY2024 · Scorecardonly one with it | —— | —— | —— | —— | —— | —— | 100% passed— |
| Shareholder returns checks (Higher is better) | —— | 4 of 6FY2024 · Scorecardonly one with it | —— | —— | —— | —— | —— | —— | 67% passed— |
| Dividends | |||||||||
| Dividend yield (Higher is better) | ———— | 0.6%FY2024 · SEConly one with it41st— | ———— | ———— | ———— | ———— | ———— | ———— | 0.6%— |
| Shareholder yield (Higher is better) | ———— | 0.8%FY2024 · SEConly one with it28th— | ———— | ———— | ———— | ———— | ———— | ———— | 0.8%— |
| Dividend payout (Better neither way: ranked highest first) | ———— | 11.8%FY2024 · SEConly one with it25th— | ———— | ———— | ———— | ———— | ———— | ———— | 11.8%— |
| Dividend per share (Better neither way: ranked highest first) | —— | $0.47FY2024 · SEConly one with it | —— | —— | —— | —— | —— | —— | $0.47— |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Dhani: National Stock Exchange of India, daily market-cap file; Dr. Reddy's Laboratories Limited: National Stock Exchange of India, daily market-cap file; Sun Pharmaceutical Industries Limited: National Stock Exchange of India, daily market-cap file; Divi's Laboratories Limited: National Stock Exchange of India, daily market-cap file; Cipla Limited: National Stock Exchange of India, daily market-cap file; Apollo Hospitals Enterprise Limited: National Stock Exchange of India, daily market-cap file; Torrent Pharmaceuticals Limited: National Stock Exchange of India, daily market-cap file; Zydus Lifesciences Limited: National Stock Exchange of India, daily market-cap file.
Where each stands in its sector and country: Operating margin#
The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.
| Company | Operating margin | In its sector | In its country |
|---|---|---|---|
| Dhani | — | — | — |
| Dr. Reddy's Laboratories Limited | 22.1%FY2024 | 90th percentile in Healthcaremedian -7.7%, 674 companies | — |
| Sun Pharmaceutical Industries Limited | — | — | — |
| Divi's Laboratories Limited | — | — | — |
| Cipla Limited | — | — | — |
| Apollo Hospitals Enterprise Limited | — | — | — |
| Torrent Pharmaceuticals Limited | — | — | — |
| Zydus Lifesciences Limited | — | — | — |
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Rank in the group
Ranks need two fiscal years with the figure for at least two of these companies.
| Fiscal year | Dhani | Dr. Reddy's Laboratories Limited | Sun Pharmaceutical Industries Limited | Divi's Laboratories Limited | Cipla Limited | Apollo Hospitals Enterprise Limited | Torrent Pharmaceuticals Limited | Zydus Lifesciences Limited |
|---|---|---|---|---|---|---|---|---|
| 2024 | — | $3.9 BSEC | — | — | — | — | — | — |
| 2023 | — | $3.4 BSEC | — | — | — | — | — | — |
| 2022 | — | $3.1 BSEC | — | — | — | — | — | — |
| 2021 | — | $2.9 BSEC | — | — | — | — | — | — |
| 2020 | — | $2.6 BSEC | — | — | — | — | — | — |
| 2019 | — | $2.5 BSEC | — | — | — | — | — | — |
| 2018 | — | $2.2 BSEC | — | — | — | — | — | — |
| 2017 | — | $2.2 BSEC | — | — | — | — | — | — |
| 2016 | — | $2.1 BSEC | — | — | — | — | — | — |
| 2015 | — | $2.4 BSEC | — | — | — | — | — | — |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.
Suggested peers of Dhani#
Companies of the same industry first, then the same sector, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- Dr. Reddy's Laboratories LimitedDRREDDY.BO · 🇮🇳 IndiaSame sector: Healthcare (Pharmaceutical) · Same country: India · Ratios of the last two fiscal years on fileMarket cap $12.5 B (Nov 20, 2026) · revenue $3.6 B (year to March 2026)45 of 100 (industry or sector 25 + country 15 + figures on file 5)In the group
- Sun Pharmaceutical Industries LimitedSUNPHARMA.NS · 🇮🇳 IndiaSame sector: Healthcare (Pharmaceutical) · Same country: IndiaMarket cap $48.8 B (Nov 20, 2026) · revenue $6.3 B (year to March 2026)40 of 100 (industry or sector 25 + country 15)In the group
- Divi's Laboratories LimitedDIVISLAB.NS · 🇮🇳 IndiaSame sector: Healthcare (Pharmaceutical) · Same country: IndiaMarket cap $32.0 B (Nov 20, 2026) · revenue $1.1 B (year to March 2026)40 of 100 (industry or sector 25 + country 15)In the group
- Cipla LimitedCIPLA.BO · 🇮🇳 IndiaSame sector: Healthcare (Pharmaceutical) · Same country: IndiaMarket cap $12.3 B (Nov 20, 2026) · revenue $3.0 B (year to March 2026)40 of 100 (industry or sector 25 + country 15)In the group
- Apollo Hospitals Enterprise LimitedAPOLLOHOSP.NS · 🇮🇳 IndiaSame sector: Healthcare (Medical Care Facilities) · Same country: IndiaMarket cap $14.3 B (Nov 20, 2026) · revenue $2.7 B (year to March 2026)40 of 100 (industry or sector 25 + country 15)In the group
- Torrent Pharmaceuticals LimitedTORNTPHARM.NS · 🇮🇳 IndiaSame sector: Healthcare (Pharmaceutical) · Same country: IndiaMarket cap $19.2 B (Nov 20, 2026) · revenue $1.5 B (year to March 2026)40 of 100 (industry or sector 25 + country 15)In the group
- Zydus Lifesciences LimitedZYDUSLIFE.NS · 🇮🇳 IndiaSame sector: Healthcare (Pharmaceutical) · Same country: IndiaMarket cap $12.9 B (Nov 20, 2026) · revenue $2.9 B (year to March 2026)40 of 100 (industry or sector 25 + country 15)In the group
- Max Healthcare Institute LimitedMAXHEALTH.BO · 🇮🇳 IndiaSame sector: Healthcare · Same country: IndiaMarket cap $11.4 B (Nov 20, 2026) · revenue $888 M (year to March 2026)40 of 100 (industry or sector 25 + country 15)+ Add
- Abbott India LimitedABBOTINDIA.BO · 🇮🇳 IndiaSame sector: Healthcare (Pharmaceutical) · Same country: IndiaMarket cap $6.1 B (Nov 20, 2026) · revenue $748 M (year to March 2026)40 of 100 (industry or sector 25 + country 15)+ Add
- Aurobindo Pharma LimitedAUROPHARMA.NS · 🇮🇳 IndiaSame sector: Healthcare (Pharmaceutical) · Same country: IndiaMarket cap $11.2 B (Nov 20, 2026) · revenue $3.6 B (year to March 2026)40 of 100 (industry or sector 25 + country 15)+ Add
- Alkem Laboratories LimitedALKEM.NS · 🇮🇳 IndiaSame sector: Healthcare (Pharmaceutical) · Same country: IndiaMarket cap $6.7 B (Nov 20, 2026) · revenue $1.6 B (year to March 2026)40 of 100 (industry or sector 25 + country 15)+ Add
- Lupin LimitedLUPIN.BO · 🇮🇳 IndiaSame sector: Healthcare (Pharmaceutical) · Same country: IndiaMarket cap $9.9 B (Nov 20, 2026) · revenue $3.0 B (year to March 2026)40 of 100 (industry or sector 25 + country 15)+ Add
Any figure over the years, other peers or a saved group: open this group in the peer workspace.